Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

NCT06801834 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

695

Enrollment

INDUSTRY

Sponsor class

Conditions

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Interventions

DRUG: Sacituzumab Govitecan (SG)
DRUG: Topotecan
DRUG: Amrubicin (Japan only)
DRUG: Lurbinectedin (regions/countries where approved and available)

Sponsor

Gilead Sciences